Updated: Novartis revamps cardiovascular commercial strategy as Entresto patent cliff looms
With its decade-long US patent for Entresto set to come to an end in a few months, Novartis has started to overhaul its commercial approach. The drugmaker is laying off hundreds of employees and will ...
With its decade-long US patent for Entresto set to come to an end in a few months, Novartis has started to overhaul its commercial approach. The drugmaker is laying off hundreds of employees and will ...
